Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A promising experimental antidepressant developed by Contineum Therapeutics and Johnson & Johnson has hit a wall. The drug, JNJ-5120 (PIPE-307), failed to meet its primary efficacy endpoint in a mid-stage trial for major depressive disorder (MDD). J&J is reviewing the full data to decide next steps, while Contineum shares dropped nearly 8% after hours.
A closely watched experimental antidepressant has failed its mid-stage test. JNJ-5120 (also known as PIPE-307), developed by Contineum Therapeutics in partnership with Johnson & Johnson, did not meet its primary efficacy endpoint in a Phase 2 trial for major depressive disorder (MDD). The trial measured improvement on a standard depression rating scale at day five versus placebo — and the drug didn't clear the bar.
What made this drug stand out was its mechanism: it targets the M1 brain receptor and was designed to work within days, a potential advantage over traditional antidepressants that can take weeks to kick in. On the safety front, the drug was well-tolerated with no new signals — but efficacy is what counts. This is also the second setback for PIPE-307, which previously failed a multiple sclerosis trial in 2025.
By the Numbers:
Why it matters: MDD is one of the most prevalent mental health conditions in the U.S., and the need for faster-acting treatments is significant. This setback underscores the difficulty of developing novel antidepressants, even with a well-resourced partner like J&J. The broader trial data is still under review, leaving some uncertainty about the program's future direction.
